ck when we were doing randomized clinical trials that these adverse events were occurring, many of them were oddly delayed and atypical for a vaccine trial. This is totally new technology and that kind of gets at the core is I think one of our problems here is the assumption that this is like every other vaccine we have ever seen and it’s not. It’s very different technology.”
